Bayer Plans to Double Down on US Pharma R&D in 2023

Bayer plans to substantially increase investment in U.S.-based pharmaceutical R&D, earmarking $1 billion to invest stateside in 2023.

The company’s stock has been on a steady decline the past five years, settling in around $15 per share as of Thursday. Compared to fellow pharmaceutical big dogs – Pfizer is trading around $40, Novartis double that, and Sanofi at around $47 – there's plenty of room for growth.